Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AN2690, 5% · 2 trials · 1 indication
No clinical evidence of onychomycosis as evidenced by normal toenail plate, no onycholysis, and no subungual hyperkeratosis, and negative KOH wet mount and negative fungal culture.
| Arm | Type | Description |
|---|---|---|
| AN2690 Topical Solution, 5% | EXPERIMENTAL | AN2690 Topical Solution, 5% |
| Solution Vehicle | PLACEBO_COMPARATOR | Solution Vehicle |
| Name | Type | Description |
|---|---|---|
| AN2690 Topical Solution, 5% | DRUG | AN2690 Topical Solution, 5%, applied once daily for 48 weeks |
| Solution Vehicle | DRUG | AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks |
Inclusion Criteria: * Clinical diagnosis of distal subungual onychomycosis affecting at least one great toenail * KOH positive at screening * Willingness not to use any other products including nail polish applied to the toenails during the study * Women of childbearing potential who are currently ...
AN2690 is an investigational small molecule being developed for the treatment of onychomycosis, a fungal infection of the nail. It is specifically studied for distal, subungual onychomycosis and onychomycosis of the toenails. The drug is administered as a topical solution.
AN2690 is being developed by Pfizer, Inc. (NYSE: PFE). The company has sponsored clinical trials evaluating the drug's safety and efficacy in patients with onychomycosis of the toenail.
AN2690 is in Phase 2 clinical development. While some completed trials were Phase 1 and Phase 3, the current development stage is Phase 2. The drug is investigational and has not been approved by regulatory authorities.
AN2690 has been studied in six completed clinical trials with a total enrollment of 1,198 participants. Key trials include NCT00679523, a Phase 2 study in Mexico, and NCT01270971 and NCT01302119, both Phase 3 studies in the United States and Canada.
AN2690 is the investigational code name for the drug also known as tavaborole. Pfizer has studied this topical antifungal under both names in clinical trials for onychomycosis of the toenails.